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Abstract
Background: Conditional transgenic models have established that tumors require sustained oncogene activation for tumor
maintenance, exhibiting the phenomenon known as ‘‘oncogene-addiction.’’ However, most cancers are caused by multiple
genetic events making it difficult to determine which oncogenes or combination of oncogenes will be the most effective
targets for their treatment.
Methodology/Principal Findings: To examine how the MYC and K-ras
G12D oncogenes cooperate for the initiation and
maintenance of tumorigenesis, we generated double conditional transgenic tumor models of lung adenocarcinoma and
lymphoma. The ability of MYC and K-ras
G12D to cooperate for tumorigenesis and the ability of the inactivation of these
oncogenes to result in tumor regression depended upon the specific tissue context. MYC-, K-ras
G12D- or MYC/K-ras
G12D-
induced lymphomas exhibited sustained regression upon the inactivation of either or both oncogenes. However, in marked
contrast, MYC-induced lung tumors failed to regress completely upon oncogene inactivation; whereas K-ras
G12D-induced
lung tumors regressed completely. Importantly, the combined inactivation of both MYC and K-ras
G12D resulted more
frequently in complete lung tumor regression. To account for the different roles of MYC and K-ras
G12D in maintenance of
lung tumors, we found that the down-stream mediators of K-ras
G12D signaling, Stat3 and Stat5, are dephosphorylated
following conditional K-ras
G12D but not MYC inactivation. In contrast, Stat3 becomes dephosphorylated in lymphoma cells
upon inactivation of MYC and/or K-ras
G12D. Interestingly, MYC-induced lung tumors that failed to regress upon MYC
inactivation were found to have persistent Stat3 and Stat5 phosphorylation.
Conclusions/Significance: Taken together, our findings point to the importance of the K-Ras and associated down-stream
Stat effector pathways in the initiation and maintenance of lymphomas and lung tumors. We suggest that combined
targeting of oncogenic pathways is more likely to be effective in the treatment of lung cancers and lymphomas.
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Introduction
Cancer is largely caused by the summation of activated
oncogenes and inactivated tumor-suppressors that occur in a
permissive epigenetic milieu resulting in various pathologic features:
autonomous proliferation, immortalization, blocked differentiation,
the induction of angiogenesis, capacity for invasion, resistance to
apoptosis and genomic instability [1]. Transgenic mouse models
have been a valuable means to identify cooperating oncogenic
events relevant to human tumorigenesis. A classic example is the
forced coexpression of c-myc and v-Ha-ras oncogenes in vivo
resulting in a strongly synergistic tumorigenesis phenotype [2].
MYC encodes a transcription factor that regulates the expression of
a multitude of genes involved in regulating cellular proliferation and
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pathologic features of cancer as described above [3,4]. K-ras
encodes a low-molecular weight GTP-binding protein responsible
for transmitting signals from receptor tyrosine kinases to down-
stream modulators of cell growth and survival [5,6] and has been
shown to stabilize the MYC protein [7]. Thus, MYC and ras
cooperate to induce tumorigenesis through multiple mechanisms.
Conditional mouse models allowing temporal control of
oncogene expression have become increasingly important for
teasing apart the tumorigenesis pathways in adult tissue compart-
ments [8]. Comparison of different transgenic systems would also
suggest that tissue type plays a role on the ability of oncogenes to
promote tumorigenesis [9,10]. Conditional transgenic tumor
models have permitted the investigation of how oncogenes not
only initiate but maintain tumorigenesis in different tissue and
developmental contexts. Using these models, it has been
established that many experimental mouse tumors exhibit the
phenomenon of oncogene addiction [11,12], whereby the
inactivation of a single oncogene has been shown to be sufficient
to induce sustained tumor regression [13–30]. Human tumors also
appear to exhibit oncogene addiction [31–33]. Most notably,
chronic myelogenous leukemia (CML) [34,35] and gastrointestinal
stromal tumor (GIST) are highly sensitive to treatment with the
tyrosine kinase inhibitor, imatinib [36].
Since most human cancers are genetically complex and are
associated with the activation of more than one oncogene,
strategies targeting multiple oncogenes appear to be a logical
approach for the treatment of human cancers [1,37,38]. Notably,
elegant studies illustrated that breast adenocarcinomas induced by
conditional MYC overexpression but that also subsequently
develop mutations in K-Ras fail to undergo sustained regression
upon MYC inactivation [16,17]. These results suggest that the
combined inactivation of both MYC and mutant Ras may be
more effective in inducing sustained tumor regression. However,
to date it has not been directly examined if the coordinate
inactivation of both MYC and mutant Ras would be more
effective in inducing sustained tumor regression.
To study how MYC and K-ras
G12D cooperate for the initiation
and maintenance of tumorigenesis, we have generated double
conditional transgenic mouse models of lymphoma and lung
adenocarcinoma. MYC-, K-ras
G12D- or MYC/K-ras
G12D-induced
lymphomas exhibited sustained regression upon single or double
oncogene inactivation. Interestingly, in contrast to most MYC-
induced tumor models, MYC-induced lung tumors were not
oncogene-addicted; whereas K-ras
G12D inactivation did induce
complete tumor regression in K-ras
G12D–induced lung tumors.
Furthermore, the combined inactivation of MYC and K-ras
G12D
was associated with reversible lung tumorigenesis. In addition, we
observed that down stream K-Ras effector, Stat3, was down-
regulated upon oncogene inactivation in lung tumors and
lymphomas that regressed. However, non-regressing MYC-
induced lung tumors were found to have aberrantly active Stat3
signaling. These data have important implications for treatment
strategies where use of multiple targeted agents is being considered
and highlight the significance of the K-Ras and Stat pathways for
tumorigenesis and tumor maintenance.
Results
MYC inactivation alone fails to induce regression of lung
cancer
To examine the role of MYC in the initiation and maintenance
of tumorigenesis, transgenic mice were generated that exhibit
conditional expression of the human c-MYC oncogene (referred to
as MYC from now on) by crossing TetO-MYC transgenic mice [15]
with the CCSP-rtTA transgenic line [39] generating CCSP-rtTA/
TetO- MYC mice (now termed CM; see Figure 1A). The CCSP-rtTA
mouse line contains the Clara cell secretory protein (CCSP or
CC10) promoter which drives expression of the reverse tetracy-
cline transactivating protein (rtTA) in lung Clara cells, alveolar
Type II pneumocytes and some other non-ciliated bronchial and
bronchiolar epithelial cells [23,39]. To verify conditional regula-
tion, CM mice were examined for MYC expression using
quantitative real-time polymerase chain reaction (qRT-PCR).
The addition of doxycycline induced expression of MYC
transcripts 380-fold in the lung with no appreciable expression
in non-induced lung tissue or induced liver (Figure 1B). Similar to
previous reports using the CCSP-rtTA line, the kinetics of
inactivation revealed background MYC expression by 3-days
after doxycycline withdrawal [23,39]. Examination for MYC
protein revealed similar robust inducible regulation by western
blotting (Figure 1C) and immunohistochemical (IHC) analysis in
CM lung tissue (Figure 1D–E). Notably, two target genes of MYC,
ornithine decarboxylase (ODC) and nucleolin [3], were found to
exhibit expression that was coordinately regulated in a conditional
manner as expected from a functional MYC protein (Figure S1).
Thus, we have developed a conditional model for the expression of
MYC in the lung.
Induction of MYC in the lung epithelium by the administration
of doxycycline in the drinking water of CM mice uniformly
resulted in tumorigenesis (Figure 2A) that on histologic examina-
tion were consistent with adenomas or adenocarcinomas
(Figure 2C–D) [40]. Tumors were composed of cuboidal to
columnar cells lining alveoli frequently containing vacuolated
tumor cells, multiple nucleoli and mitoses. Using the consensus
classification system as developed by Yu and colleagues, these
tumors would be classified as adenoma–mixed subtype (1.2.1.2.3)
and adenocarcinoma–NOS (1.2.3.2.5) [40]. Activated tumor cells
stained intensely for MYC protein by IHC analysis (Figure 2J) and
were TTF-1 positive as expected (data not shown). To enhance
detection and allow serial monitoring of lung tumors during
growth and following interventions in our study, micro-computed
tomography (mCT) was performed on cohorts of mice for the
detection of millimeter sized lesions (Figure 2B). CM mice
developed tumors with a median latency of 52 weeks as detected
by mCT screening usually well before clinical signs developed. CM
mice usually developed 1–2 dominant tumors that were located
more centrally in the mediastinum (Figure 2B). Thus, MYC
induction by the CCSP promoter is sufficient to induce lung
adenocarcinomas.
To simulate MYC targeted treatment and evaluate if MYC
inactivation was sufficient to reverse lung tumorigenesis, doxycy-
cline treatment was removed to suppress expression of the
transgene. Surprisingly, 98% (n=51) of tumor bearing CM mice
did not exhibit complete tumor regression following doxycycline
withdrawal as demonstrated by gross examination on necropsy,
radiographically and/or histologically (Figure 2E–H). Only 1 out
of 8 CM mice demonstrated volumetric tumor regression greater
than 60% by radiographic exam following 6 weeks of doxycycline
withdrawal (and see below). A trivial explanation for doxycycline-
independent tumor viability could be either the aberrant
expression of MYC independent of doxycycline or endogenous
upregulation of murine c-Myc. To address this possibility qRT-
PCR and IHC were performed on tissue from mice in which
MYC was inactivated but the tumors had not regressed. No
transgene or protein expression of MYC were detected (Figure 2I–
K and data not shown, n=6). Since the anti-MYC antibody used
for IHC in our study also cross reacts with murine c-Myc, we
Dual-Oncogene Inhibition Model
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c-Myc (Figure 2J–K). Taken together these results suggest
continuously activated CM mice develop lung tumors that become
independent of MYC for tumor maintenance.
MYC and K-ras
G12D cooperation for tumorigenesis is
dependent on tissue type
We were surprised to find that CM tumors were independent of
MYC, since a multitude of previous studies have demonstrated
that MYC-induced tumors exhibit complete tumor regression
upon MYC inactivation [13–15,17,21,22]. Studies demonstrated a
subset of breast tumors induced by MYC overexpression that fail
to undergo sustained regression upon MYC inactivation have
mutations in K-Ras [16,17]. To evaluate in our conditional lung
model if MYC and K-Ras cooperate, we utilized a conditional
mutant K-ras
G12D line previously described, CCSP-rtTA/TetO-K-
ras
G12D (now called CR) [23]. CM and CR were then used to
produce the bi-conditional animals CCSP-rtTA/TetO- MYC/TetO-
K-ras
G12D (or CMR), which upon doxycycline administration
simultaneously overexpress both oncogenes under the control of
the CCSP promoter in lung and as described below in lung tumors
(Figure S2). At 3–4 weeks of age cohorts of CM, CR and CMR
mice were treated with doxycycline and screened using physical
exam and mCT screening. As described above, CM mice
developed lung tumors with a median latency of 52 weeks
(Figure 3A). Upon doxycycline treatment, CR mice developed
lung adenocarcinomas with a median latency of 26 weeks.
Surprisingly, CMR mice developed lung adenomas and adeno-
carcinomas (Figure 4A) with a latency of 36 weeks similar to the
CR mice (Figure 3A; not significantly different by log-rank
analysis, p.0.05). Thus, in the setting of adult lung epithelium
MYC and K-ras
G12D failed to cooperate to induce accelerated
tumorigenesis.
We were surprised that the conditional MYC and K-ras
G12D
oncogenes did not cooperate to induce lung tumorigenesis. To
evaluate if these transgenes would cooperate in another tissue
setting, we induced expression of either oncogene alone or
together in lymphocytes utilizing an Em-SR-tTA line (data not
shown). In contrast to what we observed in the lung, we found that
MYC (LM) was a much more potent oncogene than K-ras
G12D
(LR) at inducing lymphomas with a median latency of tumor onset
of 13 weeks versus more than 100 weeks (Figure 3B; p,0.0001 by
log rank). Moreover, we found that MYC and K-ras
G12D cooperate
to induce tumorigenesis with a reduced median latency of 5 weeks
(all curves different, p,0.0001 by log rank). Thus, MYC and K-
ras
G12D cooperate to induce lymphoma but not lung adenocarci-
noma.
Combined MYC/K-ras
G12D inactivation induces complete
tumor regression
We speculated that in our MYC-induced lung tumors,
activation of the Ras signaling pathway may provide a means to
bypass the requirement for MYC, as has been previously suggested
[16,17]. To directly test this hypothesis, we simulated double
targeted treatment of MYC and K-ras
G12D using dual conditional
CMR tumor laden mice by inactivating both oncogenes
(Figure 4B–F) and then comparing similarly to the single CM
and CR mice. Serial mCT imaging was performed on cohorts of
Figure 1. Generation and validation of a murine conditional lung specific MYC model. (A) A mouse line containing the Clara cell secretory
protein (CCSP or CC10) promoter driving the reverse tetracycline transactivating protein (rtTA) is crossed with a line containing MYC under the
control of the tetracycline-responsive promoter (TetO). In the bitransgenic animal, CCSP-rtTA/TetO-c-MYC (or CM), absence of doxycycline prevents
rtTA protein from binding and activating the TetO promoter. Addition of doxycycline triggers a conformational change which enables TetO binding,
activation and MYC transcription. (B) Quantitative real-time reverse transcriptase-PCR (qRT-PCR) using primers specific for the MYC transgene
demonstrate that bitransgenic CM animals have robust conditional and lung restricted expression of MYC (n.=3; see Methods for specifics). (C)
Western blotting of tissue from bitransgenic CM animals using a human specific MYC antibody (9E10) reveals similar robust MYC protein expression
in a conditional and lung restricted manner. Immunohistochemical staining with a cross species reacting MYC antibody (C19) revealed similar
conditional MYC expression as confirmed by (D) MYC inactivated and (E) MYC activated CM lungs.
doi:10.1371/journal.pone.0002125.g001
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following oncogene-inactivation was performed (Figure 5A). CR
mouse tumors demonstrated complete lung tumor regression
following oncogene inactivation, as has been described previously
(n=11; Figure 5A–B) [23]. In marked contrast, CM tumors failed
to regress completely, as described above (n=8; Figure 5A–B).
Tumor bearing CMR mice on the whole exhibited tumor
regression intermediate to that of the CR and CM mice following
dual oncogene-inactivation of MYC and K-ras
G12D oncogenes
(n=10; Figure 5A–B). However as predicted, 40% of the
individual CMR-induced lung tumors analyzed showed complete
tumor regression equal to those from CR mice following
doxycycline withdrawal (Figure 5B). By qRT-PCR and IHC, we
confirmed that MYC, transgenic K-ras
G12D and endogenous K-Ras
were not expressed in the inactivated CMR lung tumors and
CMR tumors were indeed inactivated for both oncogenes
(Figure 4B–F). Altogether, these data suggest that activation of
the K-Ras signaling pathway is an essential rate-limiting event
during lung tumorigenesis. Moreover, our observation that the
combined inactivation of both MYC and K-ras
G12D induced lung
tumor regression more effectively suggests that the K-Ras pathway
may be an important target for the treatment of lung cancer.
From these results, we speculated that K-Ras may be mutated in
MYC-induced lung tumors, as has been observed in MYC-
induced breast tumors [16,17,20]. To address this possibility, we
sequenced three MYC-inactivated CM tumors (or derived cell
lines) for mutations in K-Ras but were unable to detect any hotspot
activating mutations (Figure S3). Therefore, activating mutations
of K-ras were not a common occurrence and was not an
explanation for MYC independence in our lung model, in contrast
Figure 2. Conditional expression of MYC in the lung predisposes to bronchiogenic adenocarcinomas that are oncogene-
independent. (A) MYC expression in the lung results in lung adenocarcinomas as shown (B) radiographically and (C & D) microscopically. MYC-
induced tumors after 10 weeks of MYC-inactivation (removal of doxycycline) are still present on (E) gross examination, (F) radiographically and (G & H)
microscopically (n.=10). Necropsy photographs demonstrate the thorax with tumors marked by blue arrowheads (A & E). MicroCT was used to
serially monitor the mice and representative axial images are shown with tumors marked by blue arrowheads (B & F); S–spine and H–heart. H&E
histology of germane sections show viable adenocarcinoma cells (C, D, G and H). To rule out the possibility that MYC-induced lung tumors had
developed doxycycline (or TetO)-dysregulated MYC expression, inactivated MYC-induced lung tumors were examined for spurious expression of MYC
at the mRNA and protein level. (I) qRT-PCR analysis of MYC-induced lung tumors from CM mice that had been inactivated for greater than 10 weeks
demonstrated no expression of the MYC transgene in contrast to a MYC-induced tumor that had never been inactivated. Representative
immunohistochemical analysis (performed like Figure 1D) of an (K) inactivated MYC-induced tumor also showed lack of MYC transgene product and
endogenous murine MYC protein compared to (J) a MYC-induced positive tumor control (.=3-9 tumors for .=3 mice per experiment).
doi:10.1371/journal.pone.0002125.g002
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Other components of the K-Ras effector pathway were obvious
next candidates and were investigated as described below.
Notably, in the lymphoma model, inactivation of MYC (LM
Off), K-ras
G12D (LR Off) or MYC/K-ras
G12D together (LMR Off)
were each able to induce complete regression of lymphomas and
extend tumor free survival (Figure 5C; no difference by log rank
analysis, p.0.05). For lymphomas, inactivation of MYC or K-
ras
G12D alone or both MYC/K-ras
G12D induced reversible tumor-
igenesis. In contrast, single K-ras
G12D and dual MYC/K-ras
G12D
inactivation induced reversible lung tumorigenesis, but MYC
inactivation alone failed to reverse tumorigenesis. Thus, whether
MYC induces reversible tumorigenesis alone is dependent upon
the specific tumor context.
Tumor regression is associated with the
dephosphorylation of Stat3
Our results suggested that the K-Ras signaling pathway is
crucial for both the initiation and maintenance of lung
tumorigenesis. Important upstream and downstream regulators
of the K-Ras pathway are the epidermal growth factor receptor
(EGFR) and Erk1/2, Akt1 and Stat3/5, respectively [27,41–50].
The upstream effector, EGFR, was not found to be phosphory-
lated in any of our MYC- or K-ras
G12D-induced lung tumors by
IHC (data not shown) and as described previously for K-Ras-
induced lung tumors [27]. As expected, we observed phosphor-
ylation of Erk1/2 in K-ras
G12D-induced tumors decrease upon K-
ras
G12D inactivation (CR; Figure 6A). However, there was no
evidence for phosphorylated-Erk1/2 staining by IHC in MYC-
induced lung tumors. Analogously we observed phospho-Akt1
staining in the CR lung tumors decrease upon K-ras
G12D
inactivation (Figure 6B). We observed only minimal changes in
the phosphorylation of Akt1 in CM lung tumors upon inactivation
of MYC. K-ras
G12D-induced lung tumors exhibited robust
conditional Stat3 and Stat5 phosphorylation that was dependent
on K-ras
G12D activation (Figure 6C–D). In contrast, MYC-induced
tumors had cells that stained highly positive for both phospho-
Stat3 and phospho-Stat5, and a large proportion of highly positive
phospho-Stat3 and phospho-Stat5 cells remained after MYC
inactivation (Figure 6C–D).
Surprisingly, whereas single K-ras
G12D-induced lung tumors
exhibited a high degree of Stat5 phosphorylation, dual MYC/K-
ras
G12D-induced lung tumors did not (compare Figures 6C and 7A).
CMR lung tumors did show a high degree of Stat3 phosphory-
lation that decreased upon simultaneous inactivation of both
MYC/K-ras
G12D in persistent lung tumors (Figure 7B). Thus, K-
ras
G12D- or dual MYC/K-ras
G12D-initiated lung tumors demon-
strated a decrease in Stat3 phosphorylation upon oncogene
inactivation that was associated with reversible tumorigenesis.
Next, we examined the consequences of MYC and/or K-ras
G12D
inactivation in lymphoma. LM, LR, and LMR lymphoma cells all
exhibited phosphorylation of Stat3 that decreased upon inactiva-
tion of MYC and/or K-ras
G12D (Figure 8A–B). In contrast, despite
the fact that LM, LR, and LMR lymphomas all regress upon
MYC and/or K-ras
G12D inactivation, phospho-Stat5 decreased
upon MYC, but not K-ras
G12D or dual MYC/K-ras
G12D inactiva-
tion. Collectively our results illustrate that for both MYC/K-
ras
G12D-induced lung tumors and lymphomas dephosphorylation
of Stat 3 is correlated with the ability of oncogene inactivation to
induce tumor regression.
Discussion
Targeting single oncogenes is not likely to be effective in all
cases for the treatment of human cancers [38,51]. Murine models
provide a preclinical strategy to identify which combination of
oncogenes are most likely to be effective [30,52]. To our
knowledge, our study is the first to examine experimentally using
conditional transgenic model systems if the combined inactivation
of two oncogenes is more likely to be effective in the treatment of
cancer in situ. Using our models we interrogate the role of MYC
and K-ras
G12D alone or in combination for the initiation and
maintenance of lung and hematopoietic tumorigenesis. The
inactivation of K-ras
G12D but not MYC could induce complete
tumor regression in lung adenocarcinomas; whereas in marked
contrast, single K-ras
G12D- or MYC-inactivation both succeeded in
inducing sustained regression in lymphomas. However, the
combined inactivation of both K-ras
G12D and MYC was capable
Figure 3. Cooperation during tumorigenesis by conditional
MYC and K-ras
G12D oncogenes. (A) Kaplan-Meir analysis of Tumor
Free Survival for oncogene-induced lung tumorigenesis. Single MYC-
(CM, n=51) and K-ras
G12D -induced (CR, n=41) lung tumors arose with
a median latency of 52 and 26 weeks, respectively, after conditional
oncogene activation. The double conditional oncogene animals (CMR,
n=25) had a median latency that were no different than the single CR
animals by log-rank analysis suggesting that K-ras
G12D was epistatic to
MYC for lung tumorigenesis. A syngenic control cohort consisting of
wildtype mice, those with MYC/K-ras
G12D (without CCSP), CCSP alone, or
K-ras
G12D alone were fed water and never developed lung tumors
(n=8). Tumor Free Survival was scored by serial mCT imaging of animals
following addition of doxycycline at 3–4 weeks of age. (B) Kaplan-Meir
analysis of Tumor Free Survival for oncogene-induced lymphomagen-
esis. MYC-induced lymphomas (LM, n=26) arose with a median latency
of 13 weeks after conditional oncogene activation. In contrast, less than
half of the mice developed lymphoma after 100 weeks of conditional K-
ras
G12D activation (LR, n=25). The double conditional oncogene animals
(LMR, n=22) had a median latency that was significantly different than
either single oncogene line (5 weeks, p,=0.0001 by log rank),
suggesting that K-ras
G12D and MYC were cooperative for lymphoma-
genesis. Control animals fed water never developed tumors (n=6).
Tumor Free Survival was scored when animals were moribund with
tumor.
doi:10.1371/journal.pone.0002125.g003
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lymphomas.
Our data highlight two important considerations in targeted
therapeutics: first, initiation of tumorigenesis by a specific oncogene
does not mean inactivation of that specific oncogene will be
sufficient to induce tumor regression; and second, that the
consequences of the inactivation of a particular oncogene are
pointedly dependent on tissue context. Specifically, we have
demonstrated that the K-Ras pathway and its down-stream effector
Stat3 are correlated with the ability of K-ras
G12D or MYC to initiate
lung tumorigenesis and that down regulation of the K-Ras/Stat
pathway is strongly correlated with lung tumor and lymphoma
Figure 4. Conditional expression of MYC/K-ras
G12D in the lung predisposes to bronchiogenic adenocarcinomas. (A) Double MYC/K-
ras
G12D (CMR)-induced tumors have histology consistent with adenomas/adenocarcinomas similar to MYC- and K-ras
G12D-induced tumors on H&E. (B)
To rule out the possibility that the double oncogene-induced lung tumors had developed doxycycline (or TetO)-dysregulated MYC or K-ras
G12D
expression, inactivated double oncogene-induced lung tumors were examined for spurious expression of MYC and K-ras
G12D at the mRNA and/or
protein level. qRT-PCR analysis of double oncogene-induced lung tumors from CMR mice that had been inactivated (doxycycline removed from
drinking water) for 2–9 weeks demonstrated lack of expression of the MYC transgene in contrast to a MYC-induced tumor that had never been
inactivated. Immunohistochemical analysis (performed like Figure 1D) on similar (C) inactivated double oncogene-induced tumors also showed lack
of MYC transgene product and endogenous murine MYC protein compared to a (D) MYC-activated tumor. qRT-PCR analysis of double oncogene-
induced lung tumors from CMR mice that had been inactivated demonstrated no expression of the (E) K-ras
G12D transgene or upregulation of (F)
endogenous murine K-ras (.=3–9 tumors for .=3 mice per experiment).
doi:10.1371/journal.pone.0002125.g004
Dual-Oncogene Inhibition Model
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dominant role in the initiation and maintenance of lung tumors.
Our experimental model system re-examines the classic
experiments first demonstrating the cooperation between c-myc
and v-Ha-ras for malignant transformation in vivo [2]. Identical to
previous results using conventional transgenic models [2], MYC
and K-ras
G12D cooperated to induce tumorigenesis in lymphocytes
(compare LM, LR and LMR mice; Figure 3B). In contrast, MYC
Figure 5. Regression of tumors following dual MYC/K-ras
G12D-oncogene inactivation. (A) Representative serial mCT images of single and
double-oncogene-induced lung tumors following withdrawal of doxycycline for 6 weeks. CR (CCSP-rtTA/TetO-K-ras
G12D, n=11) animals demonstrated
rapid tumor regression within ,2 weeks following inactivation of the oncogene. In contrast, CM (CCSP-rtTA/TetO-c-MYC, n=8) mice did not
demonstrate full tumor regression even after 6 weeks following oncogene inactivation. Interestingly, CMR (CCSP-rtTA/TetO-c-MYC/TetO-K-ras
G12D,
n=10) animals on a whole exhibited an intermediate level of tumor regression, with some tumors regressing completely, compared to the single
oncogene-induced lung tumors. (B) Left panel shows the mean with standard deviation of normalized tumor volumes from (A) at 6 weeks following
oncogene-inactivation. The relative genotype order for mean tumor regression: CR (n=11).CMR (n=8).CM (n=10); all pair-wise comparisons were
p,0.0013. The right panel demonstrates same data as the left panel but in a scatter plot form with the mean denoted as a horizontal line. (C) Kaplan-
Meir analysis of tumor-free survival of conditional lymphoma mice. Oncogene inactivation in MYC-induced lymphoma resulted in sustained
regression in more than half the mice (LM OFF, n=15). Oncogene inactivation in mice with K-ras
G12D–induced lymphoma resulted in tumor
regression and increased median survival by 12 weeks (LR OFF, n=5). Inactivating both MYC/K-ras
G12D together also resulted in tumor regression and
increased median survival by 5 weeks. There is no significant difference between inactivating MYC/K-ras
G12D together vs K-ras
G12D alone (log rank
analysis p=0.4849). Relapse free survival was scored when mice were moribund with tumor burden.
doi:10.1371/journal.pone.0002125.g005
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G12D to induce lung adenocarcinomas
(compare CM, CR and CMR mice; Figure 3A). Thus, whether or
not MYC and K-ras
G12D functionally cooperate to activate critical
tumor promoting pathways appears to depend upon the specific
tissue context. In lung adenocarcinomas induced by MYC and/or
K-ras
G12D, tumors exhibited activation of the K-Ras/Stat3
signaling pathway. Apparently, MYC activation is not capable of
initiating lung tumorigenesis without activation of the mediators of
the K-Ras/Stat3 pathway, perhaps accounting for why MYC does
not appear to cooperate with K-ras
G12D to induce lung tumori-
genesis. For lung tumorigenesis, there must be an essential role for
activation of the K-Ras pathway or downstream mediators such as
the Stat pathway. Similarly, the combined inactivation of MYC
and K-ras
G12D was now capable of reversing lung tumorigenesis in
contrast to MYC-induced lung tumors, because under these
circumstances the K-Ras pathway and presumably the down-
stream Stat3 pathway can be conditionally inactivated.
Notably, our results are highly consistent with several elegant
studies that illustrated that mutation of the K-Ras pathway in
breast tumorigenesis can reduce the dependence of tumors on
sustained MYC overexpression [16,17,20]. We acknowledge that
the differences seen between tumor initiation and maintenance
could be secondary to differences in the expression of MYC and K-
ras from the two different tissue specific promoters and/or may be
confined to the particular genetic background of the mice used in
our study. Nevertheless, we speculate that the combined
inactivation of both the MYC and K-Ras pathways in these
breast tumor models will also result in complete tumor regression.
In our lung tumor model system other genes are likely to be
somatically activated in the EGFR/BRAF/KRAS pathway or
parallel pathways that may also contribute to the escape from
the requirement of MYC expression. This is evidenced in our
study by the inactivated CM (Figure 6) and CMR (Figure 7) lung
tumors that did not demonstrate aberrant signaling in any of the
pathways we examined. Possible candidates to undergo such
mutations include a multitude of gene products described in
studies of human lung tumors [53–62], some of these studies have
implicated the EGFR/IL-6/Stat3 pathway in the pathogenesis of
lung adenocarcinomas [43,49,50,61–63]. Stat3 and Stat5 tran-
scription factors have been widely implicated in the pathogenesis
of tumors [64,65] and are known to be downstream targets of K-
Ras [27,44,48–50]. Phosphorylation of Stat3/5 promotes homo-
tetramerization, followed by nuclear translocation and increased
transcription of target genes critical for cell growth, survival, and
angiogenesis [64,65]. Persistent activation of Stat3/5 was found in
the majority of our inactivated MYC-induced lung tumors, as
evidenced by elevated phosphorylation and nuclear localization by
IHC (Figure 6C–D). Consistent with a role of Stat3/5 in
oncogene-addiction, phosphorylation of Stat3/5 has been shown
to diminish in tumor cells undergoing apoptosis upon oncogene
inactivation in vitro [41,42]. Phosphorylated Stat3/5 appears to be
particularly important for survival of human lung adenocarcinoma
Figure 6. Persistent activation of down-stream Ras signaling pathways after MYC inactivation. (A) Representative MYC-induced lung
tumors do not show phospho-Erk1/2 staining by IHC during activation (n=4) or inactivation (n=6). (B) Similarly, inactivated MYC-induced lung
tumors do not show phospho-Akt staining by IHC (n=6). Strong conditional staining for both phospho-Erk1/2 and phospho-Akt are seen in activated
(or ‘‘On’’) K-ras
G12D–induced tumors (n=3) but not inactivated (or ‘‘Off’’) tumors (n=7–8). A majority of MYC-induced lung tumors demonstrated (C)
phospho-Stat5 (4/6) and/or (D) phospho-Stat3 (6/7) staining by IHC that was independent of doxycycline which was in contrast to K-ras
G12D–induced
tumors (n=3 ‘‘On’’ & 6 ‘‘Off’’). IHC was performed similar to Figure 1D with stated antibodies with MYC-induced lung tumors that were activated or
inactivated (1–10 weeks). (E) IHC staining was scored as negative, low (,50% positive cells) or high ($50% positive cells) for phospho-Erk1/2, -Akt1,
phospho-Stat5 and phospho-Stat3 positive tumors.
doi:10.1371/journal.pone.0002125.g006
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lung cancer mouse models described above, in these EGFR
mutated lung cancers behave in an oncogene-addicted fashion
following treatment with EGFR tyrosine kinase inhibitors [33,63].
Our observations illustrate that the combined inactivation of
multiple oncogenes is more likely to be effective to treat some
cancers [30,38,51,52]. The potential of targeting multiple
oncogenic pathways in the treatment of human cancer has
recently been illustrated in brain tumor cell lines in vitro [38]. The
identification of the best gene products to therapeutically target in
cancers is very likely to be much more complicated than simply
identifying the genes mutated in a given tumor, as has recently
been illustrated in human lung cancer patients who become
resistant to tyrosine kinase inhibitors [37,51]. In this work, we
illustrate that even the knowledge of the oncogene that initiated
tumorigenesis is not necessarily sufficient to identify a gene
Figure 8. The inactivation of MYC and/or K-ras
G12D in lymphoma is associated with the dephosphorylation of Stat3. Oncogene
inactivation in lymphoma demonstrates decrease in Stat3 signaling. (A) LM lymphoma cells show decreased phospho-Stat 5 staining by flow
cytometry analysis upon oncogene inactivation, while LR and LMR lymphoma cells do not. (B) LM, LR and LMR lymphoma cells show decreased
phospho-Stat 3 staining by flow cytometry analysis following oncogene inactivation.
doi:10.1371/journal.pone.0002125.g008
Figure 7. Combined inactivation of MYC and K-ras
G12D in lung tumor cells results in a shutdown of Stat3 signaling. (A) Representative
phospho-Stat5 and (B) phospho-Stat3 IHC analysis demonstrates little to no levels of nuclear staining in cells following dual inactivation of MYC/K-
ras
G12D (n=3 ‘‘On’’ & 6 ‘‘Off’’) similar to conditional K-ras
G12D–induced tumors. MYC/K-ras #2-3 represent independent inactivated tumors with no to
highest amount of staining observed, respectively. IHC was performed similar to Figure 1D with stated antibodies with CMR-induced lung tumors
that were activated or inactivated (2–11 weeks). Adjacent bar graph panels represent scoring of individual tumors for IHC staining: negative, low
(,50% positive cells) or high ($50% positive cells) for phospho-Stat5 and phospho-Stat3 positive tumors.
doi:10.1371/journal.pone.0002125.g007
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generation of transgenic mice with multiple conditional oncogenes
is a tractable preclinical platform to define the combination of
oncogenic targets most likely to be effective in the treatment of
cancer.
Materials and Methods
Transgenic mice
The TetO-c-MYC and CCSP-rtTa transgenic lines generated
for these experiments was described previously [15]. The Em-tTA,
and K-ras4b
G12D transgenic lines were kindly provided by H.
Bujard (Universita ¨t Heidelberg, Germany), and H. Varmus
(Memorial Sloan-Kettering Cancer Center, New York), respec-
tively. Mice were mated and screened by PCR as below. MYC
and/or K-ras
G12D expression was activated in the CM, CR, and
CMR lung lines by administering doxycycline (Sigma) to the
drinking water weekly [100 mg/mL] starting at the age of 3-4
weeks. All procedures were performed in accordance with APLAC
protocols and animals were housed in a pathogen-free environ-
ment.
Oncogene Inactivation
Lung mice were followed by micro-computed tomography
(microCT) scans for a total of 16 weeks. Serial microCT scans
were performed at 210, 26, 22, 0, 2 and 6 weeks relative to
oncogene inactivation occurring at time point ‘‘0’’. Oncogenes
were inactivated in the CM, CR and CMR cohorts in week 10 by
removing doxycycline from the animals’ drinking water. Onco-
genes were inactivated in the LM, LR and LMR cohorts by
injecting mice with 100 mg of doxycycline in PBS IP and adding
doxycycline [100 mg/ml] to the drinking water weekly.
PCR genotyping
DNA wasisolated from mouse tails usingthe Qiaprep DNeasy kit
(Qiagen) in accordance with the manufacturer’s directions. The
CCSP-rtTA segment was detected using the following primers:
CCSP-F 59-ACTGCCCATTGCCCAAACAC-39 and CCSP-R
59-AAAATCTTGCCAGCTTTCCCC-39 (yielding a 440 bp
product). The TetO-Myc construct was detected with the following
primers: Myc-F 59-TAGTGAACCGTCAGATCGCCTG-39 and
Myc-R 59-TTTGATGAAGGTCTCGTCGTCC-39 (yielding a
450 bp product). TetO-K-ras
G12D and Em-SR-tTA werescreened
asdescribedpreviously [23].DNAwas amplifiedusingthefollowing
PCR protocol: 94uC denaturation for 2 minutes followed by 35
cycles of 94uC for 15 seconds, 59uC annealing for 30 seconds, and
72uC for 30 seconds, followed by a 5 minute extension at 72uC.
PCR products were resolved on a 1.5% gel.
SYBER-green quantitative RT-PCR and RT-PCR
Total RNA was isolated from tissue using the Strataprep total
RNA Miniprep Kit (Stratagene) according to the manufacturer’s
directions. Samples were treated with RQ1 RNase-Free DNase
(Promega) and RT–PCR was performed using Superscript One-
Step RT–PCR (Life Technologies) for 35 cycles with an annealing
temperature of 57uC with 0.25 mg of total RNA per sample.
Control reactions were run using Taq polymerase without RT
enzyme (Perkin Elmer). cDNA was generated from 1 mg of total
RNA using the Superscript II kit (Invitrogen Technologies). 50 mg
of cDNA equivalents were amplified for the transcript described
below in an ABI-prism 7700 (Perkin Elmer Applied Biosystems)
for 40 cycles using SYBR green PCR Master mix (Perkin Elmer
Applied Biosystems) according to manufacturer’s directions. PCR
reactions were performed in at least triplicate in a final volume of
20 mL. Thermal cycling conditions were: 95uC for 10 minutes,
followed by 40 cycles of 95uC for 15 seconds, 57uC for 30 seconds,
72uC for 30 seconds, and a dissociation stage consisting of 95uC
for 15 seconds, 60uC for 15 seconds, and 95uC for 15 seconds.
Following amplification, the data was processed with the analysis
program Sequence Detection Systems v2.2.2 (Applied Biosystems).
For each sample, the level of RNA for the genes of interest was
standardized to the level of ubiquitin within that sample;
subsequently, the level of a transcript of interest was normalized
to the expression of that transcript in wildtype lung. Primers for
qRT-PCR were the following: transgenic K-ras exon 4b (K-ras4b-
fwd 5- CAAGGACAAGGTGTACAGTTATGTGACT-3) and
downstream primer mp-1 pA (mp-1-real time-rev 5-GGCAT-
CTGCTCCTGCTTTTG-3); endogenous K-ras4b 3UTR (K-ras-
4b-UTR-fwd 5-GCAGGGTTGGGCCTTACAT-3 and K-ras-
4b-UTR rev 5-ATGCGTCGCCACATTGAAT-3); MYC (MYC
forward 59-ACCAGATCCCGGAGTTGGAA-39) and (MYC
reverse 59-CGTCGTTTCCGCAACAAGTC-39); ornithine de-
carboxylase (ODC) (ODC forward 59-CTGTGCTTCTGCT-
AGGATCAATGT-39) and (ODC reverse 59-GCCTTAACA-
CAAGCTAAACTTGCA-39); nucleolin (nucleolin forward 59-
GGAGGCCATGGAAGATGGAG-39) and (nucleolin reverse 59-
CACCTCTGCCTCCGAAACCT-39); and ubiquitin (ubiquitin
forward 59-AGCCCAGTGTTACCACCAAG-39) and (ubiquitin
reverse 59-ACCCAAGAACAAGCACAAGG-3).
Histology and Immunohistochemistry
Tissues were fixed in 10% buffered formalin for 24 h and then
transferred to 70% ethanol until embedding in paraffin. Tissue
sections 5 mm thick were cut from paraffin embedded blocks,
placed on glass slides and hematoxylin and eosin (H&E) staining
was performed using standard procedures (Stanford Histology
Core). Antibodies used in our study: c-Myc (C19) (Santa Cruz
Biotech.), phospho-AKT-S497 (Cell Signaling Tech.), phospho-
EGFR-Y1173 (Cell Signaling Tech.), phospho-Erk1/2-T202/
Y204 (Cell Signaling Tech.), phospho-Stat3-Y705 (Cell Signaling
Tech.) and phospho-Stat5-Y694 (Cell Signaling Tech.). Samples
were dewaxed in xylene and rehydrated in a graded series of
ethanols. Antigen retrieval for c-Myc, phospho-AKT and
phospho-EGFR were performed by 14 min microwave irradiation
in citrate-based Antigen Unmasking Solution (Vector Laborato-
ries, Burlingame, CA, USA). Antigen retrieval for phospho-Stat3
and -Stat5 were performed by 14 min microwave irradiation in
EDTA, pH 8.0, and antigen retrieval for phospho-Erk1/2 was
performed by10 min incubation in Pronase (Roche, Basel,
Switzerland). Endogenous peroxidases were blocked in either
3% hydrogen peroxide in deionized water (phospho-AKT, -pErk,
-EGFR and -pStat3/5) or 0.3% hydrogen peroxide in methanol
(c-Myc) for 10–20 minutes. Non-specific binding was blocked with
5–10% goat serum for 60 minutes. Primary antibodies were used
at appropriate dilutions (c-Myc, phospho-AKT, and -pErk at
1:100; phospho-Stat5 at 1:200; and phospho-Stat3 and -EGFR at
1:50) and sections incubated overnight at 4 degrees Celsius.
Detection was conducted using the Vector Elite ABC detection kit
(Vector Laboratories) with 3,39-diaminobenzidine tetrahy-
drochloride as the chromogen. Sections were counterstained with
Gill’s hematoxylin (Vector Laboratories).
Western blot analysis
Western analysis was performed using conventional techniques
[66]. Tissues were disrupted and protein was isolated using a pestle
and tube homogenizer in NP-40 lysis buffer. Equal protein was
loaded in each lane, as quantitated by the Bicinchoninic Acid (BCA)
Protein Assay (Pierce, Rockford, Illinois, United States). Proteins
Dual-Oncogene Inhibition Model
PLoS ONE | www.plosone.org 10 May 2008 | Volume 3 | Issue 5 | e2125were electrophoresed on 10% Tris-HCl polyacrylamide gels at
100 V for 60 min and transferred on PVDF membranes at 100 V
for 60 min. Blottingwas then performed as directed by the antibody
manufacturer. MYC protein expression was detected using the
9E10 antibody that recognizes human MYC (Santa Cruz Biotech.).
Computed Tomography
Micro-computed tomography (mCT) scans were performed on a
custom GEHC (London, Ontario) RS150 cone-beam scanner,
which uses a fixed anode with tungsten target source. Animals were
anesthetized with 2% isofluorane in a nitrogen/oxygen mixture.
Scans were performed at 97 mm resolution, using a 70 kV (40 mA)
beamto acquire images at286radialviewsover200degreesaround
the subject. Four frames were exposed and averaged in each
position. Data were corrected using the GEHC reconstruction
utility and volumes generated using the same application, which
were viewed using the GEHC Microview software.
Tumor Volume Measurements
We used the open source application, ITK-Snap, for segmenta-
tion of the lung nodules in three-dimensions [67]. The post-
processing of the segmented data provides the voxel counts and the
volume (cubic millimeters) and displays the shape of the segmented
structure. We calculated the volume of individual lung tumor
nodules right before and 6 weeks following oncogene-inactivation.
Volumes at 6 weeks were normalized relative to the volume before
oncogene-inactivation and all values for a given genotype were
averaged: CR, n=11; CM, n=8; and CMR, n=10.
Intracellular phospho-protein detection using flow
cytometry
LM, LR, and LMR- lymphoma derived cell lines were treated
with doxycyline in vitro. 1 million cells from each condition were
fixed for 10 minutes in 1.6% paraformaldehyde at 37uC,
permeabilized for 10 minutes in 100% methanol at room
temperature, washed twice with PBS 1% BSA, then stained with
10 ul anti-Phospho-Stat 5: Alexa-488(BD Biosciences Pharmingen)
or 10ul anti-Phospho-Stat 3: Alexa-488 (BD Biosciences Pharmin-
gen) in 100 ul PBS 1% BSA, incubated for 30 minutes in the dark
at room temperature. Finally, samples were washed once with PBS
1% BSA and then analyzed using a benchtop FACSCAN (Becton-
Dickinson) flow cytometer. 10,000 ungated events were collected
per sample and live cells were gated for analysis.
K-Ras mutation analysis
Total genomic DNA was harvested using DNeasy Blood & Tissue
Kit (Qiagen) as directed by the manufacturer and PCR amplified
using primers specific for K-Ras. PCR products were purified with a
QIAquick column (Qiagen) as directed by the manufacturer and
sequenced to detect point mutations at codons 12, 13, and 61.
Statistics
Survival graphs were generated by the product limit method of
Kaplan and Meier and log-rank analysis was utilized for
differences between proportions. Pair-wise and multiple compar-
isons were made using Mann-Whitney and Kruskal-Wallis
nonparametric tests, respectively. Analysis was facilitated using
Prism v5.0 by GraphPad.
Supporting Information
Figure S1 MYC transcriptional targets in the lung tumors. The
canonical MYC transcriptional targets (A) ornithine decarboxylase
(ODC) and (B) nucleolin were assayed by qRT-PCR as performed
in Figure 1B. This pattern of MYC target expression supports the
conditional and lung specific regulation of a functional MYC gene
product in the bitransgenic CM mice.
Found at: doi:10.1371/journal.pone.0002125.s001 (5.37 MB TIF)
Figure S2 Lung specific co-expression of MYC and K-rasG12D
transgenes in MYC/K-rasG12D mice. Genotype and lung specific
expression of (A) MYC and (B) K-rasG12D transgenes were assayed
by RT-PCR using cDNA templates generated from mRNA
extracted from lung tumors of CM, CR and CMR mice. Minus
reverse transcriptase (-RT) and water (H20) negative controls were
performed concurrently. The -RT control shown was generated
using the CMR mRNA. (C) Ubiquitin control RT-PCR.
Found at: doi:10.1371/journal.pone.0002125.s002 (3.33 MB
DOC)
Figure S3 MYC-induced lung tumors do not contain dominant
mutations in K-Ras. (A) Schematic of primers used to amplify
genomic DNA followed by sequencing of PCR products for K-Ras
and an example using CR mice tissue as a positive control. (B) Two
primary tumors and one derived cell line transplanted into SCID
mice were assayed for mutations in exon one hotspots, codon 12 and
13. (C) Similar samples assayed for exon 2 hotspot codon 61.
Found at: doi:10.1371/journal.pone.0002125.s003 (9.43 MB TIF)
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